

Press release

Stockholm, Sweden, June 3, 2024

Mendus to participate in upcoming industry conferences

Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will participate in the following upcoming industry conferences in June:

BIO International Convention

San Diego, USA, June 3-6, 2024

Mendus Business Development will attend for industry meetings.

[BIO International Convention | June 3-6, 2024 | San Diego](#)

European Hematology Association conference 2024

Madrid, Spain, June 13-16, 2024

Mendus will present data from the ADVANCE II Phase 2 trial in acute myeloid leukemia at the European Hematology Association conference (EHA), the leading European hematology conference. Abstracts are available on the conference website.

[Events | EHA Library by European Hematology Association \(EHA\) \(ehaweb.org\)](#)

ESMO Gynaecological Cancers Congress 2024

Florence, Italy, June 20-22, 2024

Mendus will present data from the ALISON Phase 1 trial in ovarian cancer at the ESMO Gynaecological Cancers Congress. Abstracts will be published on the conference website on June 17.

[ESMO Gynaecological Cancers Congress 2024](#)

For more information, please contact:

Erik Manting, CEO

E-mail: ir@mendus.com

About Mendus AB (publ)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <https://www.mendus.com/>